Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254421 · ClinicalTrials.gov registry record · Phase 2
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
A Phase 2 study of Respiratory Syncytial Virus Infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 17
- Study locations
NCT02254421 is a Phase 2 study of Respiratory Syncytial Virus Infection that has completed, run by Gilead Sciences. The registered enrollment target is 60 participants, below the 993-participant average among 4 other Respiratory Syncytial Virus Infection trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 12 states.
The verdict
NCT02254421, a Phase 2 study of Respiratory Syncytial Virus Infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 17
- Study locations
Study Summary
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Presatovir
Study Locations (17)
Other
- Hopital Saint-Louis, APHP - Paris
- Hopital Foch - Suresnes
- CHU de Bordeaux - Talence
- Seoul Saint Mary's Hospital - Seoul
- Karolinska Institutet - Stockholm
- University Clinical Basel - Basel
California
- City of Hope - Duarte
Illinois
- University of Chicago - Chicago
Maryland
- John Hopkins - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
New York
- New York Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-01-31 |
| Est. Completion | 2017-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254421
The ClinicalTrials.gov registry entry for NCT02254421 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 993-participant average among 4 other Respiratory Syncytial Virus Infection trials with a reported enrollment target (94% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02254421 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02254421 about?
NCT02254421 is a clinical study titled "Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract". The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI).
What is the current status of trial NCT02254421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2015-01-31. Estimated completion is 2017-04-17.
What conditions does trial NCT02254421 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infection.
What interventions are being tested in trial NCT02254421?
The interventions under investigation include: Placebo (DRUG), Presatovir (DRUG).
Who is sponsoring clinical trial NCT02254421?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02254421 being conducted?
This trial has 17 study locations across California, Illinois, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
COMPLETED · Phase 2
-
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
ACTIVE NOT RECRUITING · Phase 4
-
Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.